450 related articles for article (PubMed ID: 23547700)
1. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
4. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Kamel H; Johnston SC; Easton JD; Kim AS
Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
Langkilde LK; Bergholdt Asmussen M; Overgaard M
J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
Messori A; Fadda V; Maratea D; Trippoli S
J Cardiovasc Med (Hagerstown); 2013 Sep; 14(9):683-5. PubMed ID: 23032961
[No Abstract] [Full Text] [Related]
10. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
Adcock AK; Lee-Iannotti JK; Aguilar MI; Hoffman-Snyder CR; Wingerchuk DM; Wellik KE; Demaerschalk BM
Neurologist; 2012 Mar; 18(2):102-7. PubMed ID: 22367842
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
González-Juanatey JR; Álvarez-Sabin J; Lobos JM; Martínez-Rubio A; Reverter JC; Oyagüez I; González-Rojas N; Becerra V
Rev Esp Cardiol (Engl Ed); 2012 Oct; 65(10):901-10. PubMed ID: 22958943
[TBL] [Abstract][Full Text] [Related]
12. [Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation].
Silva Miguel L; Rocha E; Ferreira J
Rev Port Cardiol; 2013; 32(7-8):557-65. PubMed ID: 23890991
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
14. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Ali A; Bailey C; Abdelhafiz AH
Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Wang Y; Xie F; Kong MC; Lee LH; Ng HJ; Ko Y
Cardiovasc Drugs Ther; 2014 Dec; 28(6):575-85. PubMed ID: 25319314
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.
Sorensen SV; Kansal AR; Connolly S; Peng S; Linnehan J; Bradley-Kennedy C; Plumb JM
Thromb Haemost; 2011 May; 105(5):908-19. PubMed ID: 21431243
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
Wouters H; Thijs V; Annemans L
J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
[TBL] [Abstract][Full Text] [Related]
19. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Rognoni C; Marchetti M; Quaglini S; Liberato NL
Clin Drug Investig; 2014 Jan; 34(1):9-17. PubMed ID: 24135964
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.
Clemens A; Peng S; Brand S; Brueckmann M; Kansal A; Lim J; Noack H; Sander S; Sorensen S
Am J Cardiol; 2014 Sep; 114(6):849-55. PubMed ID: 25103918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
